Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.

Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A, Soroka SD, Corpier C, Arruda JA, Schwanauer LE, Klassen PS, Olson KA, Block GA.

Clin Nephrol. 2007 Jul;68(1):10-7.

PMID:
17703830
2.

Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units.

Szczech LA, Klassen PS, Chua B, Hedayati SS, Flanigan M, McClellan WM, Reddan DN, Rettig RA, Frankenfield DL, Owen WF Jr.

Kidney Int. 2006 Jun;69(11):2094-100.

3.

Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.

Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V.

Am J Kidney Dis. 2005 Jul;46(1):58-67.

PMID:
15983958
4.

Systolic hypertension: an overview.

Griffith TF, Klassen PS, Franklin SS.

Am Heart J. 2005 May;149(5):769-75. Review. No abstract available.

PMID:
15894956
5.

Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.

Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.

J Am Soc Nephrol. 2005 Mar;16(3):800-7. Epub 2005 Feb 2.

6.

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D.

J Clin Endocrinol Metab. 2005 Jan;90(1):135-41. Epub 2004 Nov 2.

PMID:
15522938
7.

Slowing the progression of diabetic nephropathy and its cardiovascular consequences.

McCullough PA, Bakris GL, Owen WF Jr, Klassen PS, Califf RM.

Am Heart J. 2004 Aug;148(2):243-51. Review.

PMID:
15308993
8.

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.

J Am Soc Nephrol. 2004 Aug;15(8):2208-18.

9.

Definition of proteinuria among women with HIV infection.

Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP.

Kidney Int. 2004 Apr;65(4):1519. No abstract available.

10.

Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients.

Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA.

Am J Kidney Dis. 2003 Dec;42(6):1260-9.

PMID:
14655199
11.

Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease?

Griffith TF, Reddan DN, Klassen PS, Owen WF.

Nephrol Dial Transplant. 2003 Dec;18(12):2479-82. Review. No abstract available.

PMID:
14605267
12.

Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients.

Szczech LA, Reddan DN, Klassen PS, Coladonato J, Chua B, Lowrie EG, Lazarus JM, Owen WF Jr.

Nephrol Dial Transplant. 2003 Aug;18(8):1585-91.

PMID:
12897099
13.

White blood cells as a novel mortality predictor in haemodialysis patients.

Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O'Shea S, Owen WF Jr, Lowrie EG.

Nephrol Dial Transplant. 2003 Jun;18(6):1167-73.

PMID:
12748351
14.

Regional variability in anaemia management and haemoglobin in the US.

Reddan DN, Frankenfield DL, Klassen PS, Coladonato JA, Szczech L, Johnson CA, Besarab A, Rocco M, McClellan W, Wish J, Owen WF Jr; Center for Medicare & Medicaid Services' End-Stage Renal Disease Clinical Performances Measures Workgroup.

Nephrol Dial Transplant. 2003 Jan;18(1):147-52.

PMID:
12480973
15.

Chronic kidney disease and cardiovascular risk: time to focus on therapy.

Reddan DN, Klassen PS.

J Am Soc Nephrol. 2002 Sep;13(9):2415-6. Review. No abstract available.

16.

Trends in anemia management among US hemodialysis patients.

Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, Owen WF Jr.

J Am Soc Nephrol. 2002 May;13(5):1288-95.

17.

Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.

Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr.

JAMA. 2002 Mar 27;287(12):1548-55.

PMID:
11911757
18.

Predictors of proteinuria and renal failure among women with HIV infection.

Szczech LA, Gange SJ, van der Horst C, Bartlett JA, Young M, Cohen MH, Anastos K, Klassen PS, Svetkey LP.

Kidney Int. 2002 Jan;61(1):195-202.

19.

Diagnosis and management of renovascular hypertension.

Klassen PS, Svetkey LP.

Cardiol Rev. 2000 Jan-Feb;8(1):17-29. Review.

PMID:
11174870
20.

Racial inequity in America's ESRD program.

Reddan DN, Szczech LA, Klassen PS, Owen WF Jr.

Semin Dial. 2000 Nov-Dec;13(6):399-403.

PMID:
11130265
21.

Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients.

Howell DN, Smith SR, Butterly DW, Klassen PS, Krigman HR, Burchette JL Jr, Miller SE.

Transplantation. 1999 Nov 15;68(9):1279-88.

PMID:
10573064
22.

Selenium and the immune response: 2. Enhancement of murine cytotoxic T-lymphocyte and natural killer cell cytotoxicity in vivo.

Petrie HT, Klassen LW, Klassen PS, O'Dell JR, Kay HD.

J Leukoc Biol. 1989 Mar;45(3):215-20.

PMID:
2564412

Supplemental Content

Loading ...
Support Center